Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

The kidney in type 2 diabetes therapy.

Heerspink HJ, de Zeeuw D.

Rev Diabet Stud. 2011 Fall;8(3):392-402. doi: 10.1900/RDS.2011.8.392. Epub 2011 Nov 10. Review.

2.

Albuminuria: a target for treatment of type 2 diabetic nephropathy.

de Zeeuw D.

Semin Nephrol. 2007 Mar;27(2):172-81. Review.

PMID:
17418686
3.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
5.

Management of diabetic nephropathy: Recent progress and future perspective.

Ahmad J.

Diabetes Metab Syndr. 2015 Oct-Dec;9(4):343-58. doi: 10.1016/j.dsx.2015.02.008. Epub 2015 Mar 6. Review.

PMID:
25845297
6.

Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.

Muskiet MH, Tonneijck L, Smits MM, Kramer MH, Heerspink HJ, van Raalte DH.

Lancet Diabetes Endocrinol. 2015 May;3(5):367-81. doi: 10.1016/S2213-8587(15)00030-3. Review.

PMID:
25943756
7.

Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.

Škrtić M, Cherney DZ.

Curr Opin Nephrol Hypertens. 2015 Jan;24(1):96-103. doi: 10.1097/MNH.0000000000000084. Review.

PMID:
25470017
8.

Current concepts in the management of diabetic nephropathy.

Waanders F, Visser FW, Gans RO.

Neth J Med. 2013 Nov;71(9):448-58. Review.

9.

Antihypertensive treatment and multifactorial approach for renal protection in diabetes.

Fioretto P, Solini A.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S18-21. Review.

10.
11.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
12.

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Kidney Int. 2004 Jun;65(6):2309-20.

13.

Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy.

Bretzel RG.

J Diabetes Complications. 1997 Mar-Apr;11(2):112-22. Review.

PMID:
9101397
14.

Investigational drugs for diabetic nephropathy.

Cortinovis M, Cattaneo D, Perico N, Remuzzi G.

Expert Opin Investig Drugs. 2008 Oct;17(10):1487-500. doi: 10.1517/13543784.17.10.1487 . Review.

PMID:
18808309
15.

Improvements in the Management of Diabetic Nephropathy.

Dounousi E, Duni A, Leivaditis K, Vaios V, Eleftheriadis T, Liakopoulos V.

Rev Diabet Stud. 2015 Spring-Summer;12(1-2):119-33. doi: 10.1900/RDS.2015.12.119. Epub 2015 Aug 10. Review.

16.

Detecting and controlling diabetic nephropathy: what do we know?

Appel G.

Cleve Clin J Med. 2013 Apr;80(4):209-17. doi: 10.3949/ccjm.80gr.12006.

PMID:
23547091
17.

Treatment of microalbuminuria in patients with type 2 diabetes mellitus.

Jerums G, MacIsaac RJ.

Treat Endocrinol. 2002;1(3):163-73. Review.

PMID:
15799209
19.

25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.

Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J; PRONEDI Study Group.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6. doi: 10.2215/CJN.00910113. Epub 2013 Oct 17.

20.

Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.

Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.

Horm Metab Res. 2005 Apr;37 Suppl 1:4-8.

PMID:
15918104

Supplemental Content

Support Center